France-based Servier and Oncodesign have agreed to partner on the development of LRRK2 kinase inhibitors in Parkinson’s disease. Servier to be granted an option to exclusively license one or several drug candidates as soon as they are approved to enter Phase I. Planning to fund the entire program. It is reported that Oncodesign will receive an upfront payment of €3M at the signing of the partnership and they could receive up to €320M ($360M), excluding sales royalties.
Based in France and Publicly traded, they have built expertise for anticancer therapies from target to patient. Founded in 1995, they are a biopharmaceutical company that fills in the innovation gaps in the health sector, based on its unique precision medicine platform. They have raised nearly $30 million since inception. They generate approximately $28 million per annum and operate at a small loss. They report about $9.7 million in cash and currently have a market capitalization of $49.7 million. Clearly this Servier deal will infuse potential.
Also based in France, an international pharmaceutical company governed by non-profit foundation, with its headquarters in Suresnes. It operates in 149 countries and reports turnover of $4.152 billion euros in 2017. They employ 21,700 people worldwide. They reinvest 25% of its turnover in research and development and uses all of its profits for development. They are constantly looking to invest in the following therapeutic areas: Immune-inflammatory and neuropsychiatric diseases, cancer, diabetes, as well by its activities in high-quality generic drugs. They have moved into eHealth solutions beyond drug development.